Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Oklahoma: - Cancer Centers of Southwest Oklahoma Research — Lawton, Oklahoma
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Oklahoma Cancer Specialists and Research Institute-Tulsa — Tulsa, Oklahoma
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…
Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvemen…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07000084
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Oklahoma: - Cancer Centers of Southwest Oklahoma Research — Lawton, Oklahoma
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
- Oklahoma Cancer Specialists and Research Institute-Tulsa — Tulsa, Oklahoma
Phase 2 Recruiting Industry
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04879329
Sites in Oklahoma: - OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
- OU Medical Center — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy inc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061964
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunothe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06770582
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Oklahoma: - University of Oklahoma — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Oklahoma: - University of Oklahoma Health Sciences, Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Oklahoma: - OU Health University of Oklahoma Medical Center — Oklahoma City, Oklahoma
- Stephenson Cancer Center (chemo location) — Oklahoma City, Oklahoma
- University of Oklahoma Health Science Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cel…
Sponsor: Eli Lilly and Company
NCT ID: NCT05614739
Sites in Oklahoma: - University of Oklahoma - Health Sciences Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Oklahoma: - University of Oklahoma — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Oklahoma: - OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main questions it aims to answer are: 1. what is the maximum tolerated dose and recommended dos…
Sponsor: Totus Medicines
NCT ID: NCT05683418
Sites in Oklahoma: - Stephenson Cancer Center — Oklahoma City, Oklahoma
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oklahoma: - Massive Bio SYNERGY-AI site — Tulsa, Oklahoma
NA Recruiting NIH
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for mult…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06995898
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
NA Recruiting Industry
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Sponsor: Axonics, Inc.
NCT ID: NCT06511141
Sites in Oklahoma: - Utica Park Urology — Tulsa, Oklahoma
Recruiting Industry
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-u…
Sponsor: Elephas
NCT ID: NCT07327489
Sites in Oklahoma: - Mercy Hospital - OKC — Oklahoma City, Oklahoma